Designs and develops medical devices for neurohealth disorders. Markets the NeuroStar Advanced Therapy System. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 28% a year on average.
Sales run at $149.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 33 buys and 15 sells. Management buying with its own money is usually read as a good sign.
A loss of $39.0M against $149.2M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, STIM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: STIM is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (57/100) says the stock isn’t cheap.